Company Overview and News


Add LMNX
to your dashboard

Headline News

Five Scorching Hot Strong Buy Stocks

6h zacks
As this earnings season starts to enter its later stages the market continues to extend gains. Meaningful progress on tax reform coupled with solid earnings numbers have combined to create a very bullish atmosphere for stocks. Today’s rally was broad and convincing with the small caps taking a bow and breaking out to new all-time highs along with the S&P 500. (6-0)

Medtronic (MDT) Beats on Q2 Earnings, Reiterates FY18 View

13h zacks
Medtronic plc (MDT - Free Report) reported second-quarter fiscal 2018 adjusted earnings per share (EPS) of $1.07, beating the Zacks Consensus Estimate by 8.1%. Earnings however declined 4.5% year over year.  (11-1)

Patterson Companies (PDCO) Misses on Q2 Earnings, Cuts View

13h zacks
Patterson Companies Inc. (PDCO - Free Report) reported adjusted earnings of 51 cents per share in second-quarter fiscal 2018, missing the Zacks Consensus Estimate of 54 cents. Earnings were also lower than the year-ago figure of 56 cents. Hurricanes hurt Patterson Companies’ earnings per share by approximately a penny in the quarter. (6-1)

Luminex (LMNX) Banks on FDA Approvals & Portfolio Strength

2017-11-16 zacks
On Nov 16, we issued an updated research report on Luminex Corp (LMNX - Free Report) — a manufacturer and marketer of proprietary biological testing technologies with applications throughout the life sciences and diagnostics industry. (47-0)

Here's Why Investors Should Buy Myriad Genetics Right Now

2017-11-16 zacks
Myriad Genetics, Inc. (MYGN - Free Report) has rallied 12.2% over the last three months, ahead of the S&P 500’s 6.3% gain and also better than the broader industry’s decline of 4.6%. The stock has a market cap of $2.16 billion. (44-1)

LMNX / Luminex Corp. - Stock Institutional Ownership and Shareholders - Fintel.io

2017-11-15 fintel.io
Luminex Corp. (NASDAQ:LMNX) has 164 institutional investors and shareholders that have filed 13D/G or 13F forms with the Securities Exchange Commission (SEC). These institutions hold a total of 35,046,575 shares. Largest shareholders include BlackRock Inc., Vanguard Group Inc, RGM Capital, LLC, Renaissance Technologies LLC, and Villere St Denis J & Co Llc. (33-0)

Myriad Genetics' Latest Alliance to Boost GeneSight Reach

2017-11-15 zacks
Myriad Genetics, Inc.’s (MYGN - Free Report) wholly owned subsidiary Assurex Health recently formed an alliance with the Department of Veterans Affairs (VA) in PRIME Care (PRecision Medicine In MEntal Health Care) — a multi-center and national trial to evaluate the effectiveness of GeneSight test in improving health resultsfor veterans suffering from major depressive disorder (MDD). (83-0)

Here's Why Investors Should Buy Luminex (LMNX) Right Now

2017-11-15 zacks
Luminex Corporation (LMNX - Free Report) has rallied 10.9% over the last three months, ahead of the S&P 500’s 4.8% gain and also better than the broader industry’s rise of 4.6%. The stock has a market cap of $937.5 million.The company’s current-year historical growth rate is also favorable at 53.1% as compared with 22.7% of the S&P 500 index and 17.6% of the broader industry. (83-0)

Quest Diagnostics, Clinical Genomics Ally, Oncology Strong

2017-11-14 zacks
Quest Diagnostics Inc. (DGX - Free Report) and Clinical Genomics, a major player in the field of colorectal cancer detection, jointly announced the FDA clearance of the latter’s InSure ONE. (30-0)

Weight Watchers (WTW) to Issue $500M Senior Notes Due 2025

2017-11-14 zacks
Weight Watchers International Inc. (WTW - Free Report) recently announced an offering of $500 million senior notes, due in 2025. The notes will be unsecured and will be guaranteed by the company's subsidiaries. The company intends to enter into a new $150-million revolving credit facility to refinance its existing one. (24-0)

Can Luminex Light The Way?

2017-11-14 seekingalpha
A growing number of assays on its diagnostic system continues to expand its market and revenue potential. (1-0)

Bio-Rad (BIO) Beats Earnings and Revenue Estimates in Q3

2017-11-13 zacks
Bio-Rad Laboratories, Inc. (BIO - Free Report) reported third-quarter 2017 earnings of 91 cents per share, a 46.8% surge from the year-ago figure. The bottom line also surpassed the Zacks Consensus Estimate of 33 cents by a wide margin. Notably, net income in the quarter was favorably impacted by higher sales and a significantly improved gross margin.  (36-0)

Medtronic Preliminary Sales Dip Y/Y, Hurricane Blow Lessens

2017-11-13 zacks
Medtronic plc (MDT - Free Report) announced dull preliminary sales results for second-quarter fiscal 2018. Preliminary worldwide revenues for the quarter dipped 4% year over year to $7.05 billion. The Zacks Consensus Estimate of $7.09 billion remains a tad higher than the reported preliminary revenue figure. (57-0)

BioTelemetry (BEAT) Q3 Earnings Miss, Revenues Meet Estimates

2017-11-13 zacks
BioTelemetry Inc. (BEAT - Free Report) reported third-quarter 2017 adjusted earnings of 16 cents per share, which widely missed the Zacks Consensus Estimate of 24 cents as well as the year-ago equivalent of 21 cents. (20-0)

Bruker's NANO Grows Strong, MERLIN Buyout Holds Promise

2017-11-10 zacks
On Nov 08, we issued an updated research report on Bruker Corporation (BRKR - Free Report) . The stock carries a Zacks Rank #3 (Hold). (13-0)

CUSIP: 55027E102